A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.

Phase 2

Zhejiang Cancer Hospital

Bevacizumab
Carboplatin
Paclitaxel